Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

ClinicalTrials.gov ID: NCT06561048

Public ClinicalTrials.gov record NCT06561048. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 6, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Study identification

NCT ID: NCT06561048
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 3
Lead sponsor: Corvus Pharmaceuticals, Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Interventions

Belinostat Drug
Pralatrexate Drug
Soquelitinib Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Oct 1, 2024
Primary completion: Oct 31, 2027
Completion: Nov 30, 2028
Last update posted: Apr 7, 2026

2024 – 2028

United States locations

U.S. sites: 21
U.S. states: 17
U.S. cities: 19

Facility	City	State	ZIP	Site status
City of Hope National Medical Center	Duarte	California	91010	Recruiting
University of California, Irvine	Irvine	California	92697	Recruiting
University of California San Francisco	San Francisco	California	94143	Recruiting
Yale University	New Haven	Connecticut	06520	Recruiting
Sylvester Comprehensive Cancer Center University of Miami Miller School of Medicine	Miami	Florida	33136	Recruiting
Emory University	Atlanta	Georgia	30322	Recruiting
North Western University Robert H. Lurie Comprehensive Cancer Center RHLCCC	Chicago	Illinois	60611	Recruiting
University of Iowa	Iowa City	Iowa	52242	Recruiting
University of Maryland Medical Center	Baltimore	Maryland	21201	Recruiting
Massachusetts General Hospital	Boston	Massachusetts	02114	Recruiting
Roger Cancer Center University of Michigan Health	Ann Arbor	Michigan	48109	Recruiting
Washington University in St. Louis	St Louis	Missouri	63130	Recruiting
Hackensack University Medical Center	Hackensack	New Jersey	07601	Recruiting
Icahn School of Medicine at Mount Sinai	New York	New York	10029	Recruiting
Memorial Sloan Kettering Cancer Center	New York	New York	10065	Recruiting
Weill Cornell Medicine	New York	New York	10065	Recruiting
North Carolina Cancer Hospital	Chapel Hill	North Carolina	27514	Recruiting
The Ohio State University	Columbus	Ohio	43210	Recruiting
MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
University of Washington Fred Hutch Cancer Center	Seattle	Washington	98109	Recruiting
University of Wisconsin Carbone Cancer Center	Madison	Wisconsin	53792	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT06561048, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 7, 2026 · Synced May 6, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06561048 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →